The development of the compound, called WEHI-539, is an important step towards the design of a potential new anti-cancer agent. WEHI-539 has been designed to bind and block the function of a protein called BCL-XL that normally prevents cells from dying.The death and elimination of abnormal cells in the body is an important safeguard against cancer development. But cancer cells often acquire genetic changes that allow them to bypass cell death, which also reduces the effectiveness of anti-cancer treatments such as chemotherapy.
The research was supported by the Australian Research Council, the National Health and Medical Research Council, the US Leukemia and Lymphoma Society, Cancer Council Victoria, the Australian Cancer Research Foundation and the Victorian Government.
Vanessa Solomon | EurekAlert!
Primates indispensable for regeneration of tropical forests
24.11.2014 | Deutsches Primatenzentrum GmbH - Leibniz-Institut für Primatenforschung
Clipping proteins that package genes may limit abnormal cell growth in tumors
24.11.2014 | The Mount Sinai Hospital / Mount Sinai School of Medicine
21.11.2014 | Event News
13.11.2014 | Event News
12.11.2014 | Event News
24.11.2014 | Power and Electrical Engineering
24.11.2014 | Process Engineering
24.11.2014 | Agricultural and Forestry Science